Cover Image

Update breast cancer 2020 part 4 - advanced breast cancer = Update Mammakarzinom 2020 Teil 4 – fortgeschrittenes Mammakarzinom

Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the t...

Full description

Saved in:
Bibliographic Details
Main Authors: Tesch, Hans (Author) , Müller, Volkmar (Author) , Wöckel, Achim (Author) , Ettl, Johannes (Author) , Belleville, Erik (Author) , Schütz, Florian (Author) , Hartkopf, Andreas (Author) , Thill, Marc (Author) , Huober, Jens (Author) , Fasching, Peter A. (Author) , Kolberg, Hans-Christian (Author) , Schulmeyer, Carla E. (Author) , Welslau, Manfred (Author) , Overkamp, Friedrich (Author) , Fehm, Tanja (Author) , Lux, Michael P. (Author) , Schneeweiss, Andreas (Author) , Lüftner, Diana (Author) , Janni, Wolfgang (Author)
Format: Article (Journal)
Language:English
Published: 2020-11-06
In: Geburtshilfe und Frauenheilkunde
Year: 2020, Volume: 80, Issue: 11, Pages: 1115-1122
ISSN:1438-8804
DOI:10.1055/a-1270-7481
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1270-7481
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1270-7481
Get full text
Author Notes:Hans Tesch, Volkmar Müller, Achim Wöckel, Johannes Ettl, Erik Belleville, Florian Schütz, Andreas Hartkopf, Marc Thill, Jens Huober, Peter A. Fasching, Hans-Christian Kolberg, Carla E. Schulmeyer, Manfred Welslau, Friedrich Overkamp, Tanja N. Fehm, Michael P. Lux, Andreas Schneeweiss, Diana Lüftner, Wolfgang Janni
Description
Summary:Substances with good effectiveness that intervene in specific signalling pathways have been used increasingly in recent years in the treatment of patients with advanced breast cancer, and new therapies and approaches have now been added, which actually relate to quite specific changes, such as the treatment of patients with HR+/HER2 tumours with a PIK3CA mutation. The treatment of patients with a BRCA1or BRCA2 mutation has also been improved by the introduction of PARP inhibitors. Attempts are now being made increasingly to extend treatment indications based on molecular patterns, to identify other patients who could benefit from a treatment and to integrate the newly established treatment methods in existing therapy sequences. This review articles summarises the latest information in this connection.
Item Description:Gesehen am 12.02.2021
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-1270-7481

Similar Items